Dr. Reddy’s Laboratories Allots Equity Shares Under ESOP

Meet Your ETF AI Analyst Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.An update from Dr Reddy’s Laboratories ( (RDY) ) is now available. On November 13, 2025, Dr. Reddy’s Laboratories announced the allotment of 7,430 equity shares to eligible employees under its Employees Stock Options Scheme, 2002. This move reflects the company’s commitment to employee engagement and retention, potentially enhancing its operational efficiency and stakeholder value. The most recent analyst rating on (RDY) stock is a Hold with a $14.50 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page. Spark’s Take on RDY Stock According to Spark, TipRanks’ AI Analyst, RDY is a Neutral. Dr Reddy’s Laboratories’ overall stock score is driven by strong financial performance and a reasonable valuation. However, technical analysis indicates bearish trends, and the earnings call highlights both growth opportunities and challenges, particularly in the U.S. market. The absence of significant corporate events further focuses the score on these core components. To see Spark’s full report on RDY stock, click here. More about Dr Reddy’s Laboratories Dr. Reddy’s Laboratories Limited is a pharmaceutical company based in Hyderabad, India, known for producing a wide range of generic medications, active pharmaceutical ingredients, and biologics. The company is focused on providing affordable and innovative medicines to patients worldwide and is listed on major stock exchanges including BSE, NSE, and NYSE. Average Trading Volume: 1,023,357 Technical Sentiment Signal: Hold Current Market Cap: $11.57B